Syndax Pharmaceuticals, Inc. (SNDX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
Syndax (SNDX) Q1 2026: Revuforge Drives 224% Revenue Surge, Transplant Tailwind Set to Accelerate
May 01, 2026
-
Syndax (SNDX) Q4 2025: Revuforge Net Revenue Climbs 38% on Expanded AML Penetration
February 27, 2026
-
Syndax (SNDX) Q3 2025: Revuforge Scripts Jump 25% as NPM1 Approval Triples Addressable Market
November 04, 2025
-
Syndax (SNDX) Q2 2025: Revuforge Sales Jump 43% as Early-Line Adoption Drives Multi-Year Upside
August 05, 2025
-
Syndax (SNDX) Q1 2025: Revuforge Orders Hit 44% of Priority Accounts, Fueling Commercial Ramp
July 07, 2025